| Home : June 2011 : June 03, 2011 News : BARDA EXERCISES OPTIONS WITH CANGENE WORTH US$61 MILLION UNDER BOTULISM ANTITOXIN SUPPLY CONTRACT |
BARDA EXERCISES OPTIONS WITH CANGENE WORTH US$61 MILLION UNDER BOTULISM ANTITOXIN SUPPLY CONTRACT |
June 03, 2011
Readers are referred to the cautionary notes regarding
Forward-looking Information at the end of this release
Listed TSX, Symbol: CNJ
WINNIPEG, June 3, 2011 /PRNewswire/ - Cangene Corporation (TSX: CNJ) today
announces that the Biomedical Advanced Research and Development
Authority
http://www.prnewswire.com/news-releases/barda-exercises-options-with-cangene-worth-us61-million-under-botulism-antitoxin-supply-contract-123142848.html
|
|
|
 Other Stories |
|
|
|
|
|
|
|
|
|
|
|
